References |
Top |
REF 1 |
ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
|
REF 2 |
ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
|
REF 3 |
ClinicalTrials.gov (NCT03262298) Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies
|
REF 4 |
ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
|
REF 5 |
ClinicalTrials.gov (NCT02794961) CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies
|
REF 6 |
ClinicalTrials.gov (NCT02935153) A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
|
REF 7 |
ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
|
REF 8 |
ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
|
REF 9 |
ClinicalTrials.gov (NCT02588456) Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
|
REF 10 |
ClinicalTrials.gov (NCT02650414) CD22 Redirected Autologous T Cells for ALL
|
REF 11 |
ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL
|
REF 12 |
ClinicalTrials.gov (NCT03244306) A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma
|
REF 13 |
ClinicalTrials.gov (NCT02721407) Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients
|
REF 14 |
ClinicalTrials.gov (NCT04150497) Phase I Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01). U.S. National Institutes of Health.
|
REF 15 |
Clinical pipeline report, company report or official report of Atara Biotherapeutics.
|